C12N 2760/18122
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/18122 (New viral proteins or individual genes, new structural or functional aspects of) appears on 153 US grants and 118 published applications in this corpus.
Search patents in C12N- Granted patents
- 153
- Published applications
- 118
- Assignees
- 78
- Inventors
- 292
- Latest grant
- 6 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 5 | 0 |
| 1995 | 3 | 0 |
| 1996 | 6 | 0 |
| 1997 | 3 | 0 |
| 1998 | 12 | 0 |
| 1999 | 8 | 0 |
| 2000 | 17 | 0 |
| 2001 | 9 | 0 |
| 2002 | 5 | 2 |
| 2003 | 7 | 8 |
| 2004 | 5 | 12 |
| 2005 | 5 | 4 |
| 2006 | 6 | 0 |
| 2007 | 4 | 5 |
| 2008 | 3 | 3 |
| 2009 | 6 | 6 |
| 2010 | 2 | 8 |
| 2011 | 5 | 5 |
| 2012 | 2 | 4 |
| 2013 | 3 | 1 |
| 2014 | 2 | 6 |
| 2015 | 3 | 0 |
| 2016 | 3 | 4 |
| 2017 | 0 | 1 |
| 2018 | 1 | 5 |
| 2019 | 5 | 2 |
| 2020 | 3 | 3 |
| 2021 | 2 | 8 |
| 2022 | 6 | 9 |
| 2023 | 1 | 8 |
| 2024 | 2 | 5 |
| 2025 | 5 | 8 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant herpesvirus of turkeys (HVT) and preparation method and use thereof6 Jan 2026US 12,516,353 B2Yangzhou University
- Gallid alphaherpesvirus 3 (MDV-2), a viral vector against different avian pathogens: a new vaccination strategy in the poultry industry18 Nov 2025US 12,473,572 B1FarmacolóGicos Veterinarios S.A.C.
- Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)14 Oct 2025US 12,440,552 B2University of Massachusetts
- Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease19 Aug 2025US 12,391,957 B2Icahn School of Medicine at Mount Sinai
- Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof12 Aug 2025US 12,385,068 B2Boehringer Ingelheim Animal Health USA Inc.
- Virus attenuation30 Apr 2026US 2026/0115273 A1University of Lancaster
- Fusosome compositions and uses thereof4 Dec 2025US 2025/0369018 A1Flagship Pioneering Innovations V, Inc.
- Recombinant hvt vectors expressing multiple antigens of avian pathogens and uses thereof30 Oct 2025US 2025/0333766 A1Boehringer Ingelheim Animal Health USA Inc.
- Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant17 Jul 2025US 2025/0228929 A1Icahn School of Medicine at Mount Sinai
- Multivalent kaposi sarcoma-associated herpesvirus-like particles and uses thereof22 May 2025US 2025/0161435 A1City of Hope
Most cited
By later US patents
- Recombinant new castle disease virus RNA expression systems and vaccines164US 6,146,642 AMount Sinai School of Medicine of the City University of New York · 2000
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Synthetic peptide inhibitors of HIV transmission102US 5,464,933 ADuke University · 1995